Publications by authors named "J Lunec"

Claim this Profile
C
Correction: Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
Hayden L Bell, Helen J Blair, Mankaran Singh, Anthony V Moorman, Olaf Heidenreich, John Lunec

Cancer Cell Int· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating Wild-Type Chronic Lymphocytic Leukemia.
Erhan Aptullahoglu, Mohammed Howladar, Jonathan P Wallis, Helen Marr, Scott Marshall, John Lunec

Cancers (Basel)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Systematic Review of the Molecular Mechanisms Involved in the Association Between PCOS and Endometrial and Ovarian Cancers.
M Zanjirband, M H Nasr-Esfahani, N J Curtin, Y Drew, S Sharma Saha, J Lunec

J Cell Mol Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination p53 activation and BCL-x/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
Hayden L Bell, Helen J Blair, Samantha J Jepson Gosling, Martin Galler, Daniel Astley, John Lunec

Leukemia· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in Wild-Type Chronic Lymphocytic Leukemia.
Erhan Aptullahoglu, Sirintra Nakjang, Jonathan P Wallis, Helen Marr, Scott Marshall, John Lunec

Biomedicines· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis